Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key inclusion criteria:~Eligible subjects must fulfill the following inclusion criteria:~1. Age: 18-60 years~2. A documented diagnosis of Fabry disease~3. Males: plasma and/or leucocyte alpha galactosidase activity (by activity assay) less than lower limit of normal according to the laboratory reference ranges and one or more of the characteristic features of Fabry disease~   1. Neuropathic pain~  2. Cornea verticillata~  3. Clustered angiokeratoma~4. Females: historical genetic test results consistent with Fabry mutations, or in the case of novel mutations a first-degree male relative with Fabry disease, and one or more of the characteristic features of Fabry disease~   1. Neuropathic pain~  2. Cornea verticillata~  3. Clustered angiokeratoma~5. Treatment with agalsidase alfa or agalsidase beta for at least 3 years and on a stable dose (\>80% labelled dose/kg) for at least last 6 months~6. eGFR ≥ 30 mL/min/1.73m\^2 by CKD-EPI equation at screening visit~7. Availability of at least 3 historical serum creatinine evaluations since starting agalsidase alfa or agalsidase beta treatment and not more than 2 years old~8. Female patients and male patients whose co-partners are of child-bearing potential agree to use a medically accepted, highly effective method of contraception. These include combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomised partner, or sexual abstinence~9. Patients whose clinical condition, in the opinion of the Investigator, is suitable for treatment with ERT every 4 weeks.~Key exclusion criteria:~The presence of any of the following excludes a subject from study enrollment:~1. History of anaphylaxis or Type 1 hypersensitivity reaction to agalsidase alfa or agalsidase beta~2. History of renal dialysis or transplantation~3. Linear negative slope of eGFR of ≥ 2 mL/min/1.73m\^2/year based on at least 4 serum creatinine values over approximately 2 years (including the value obtained at the screening visit)~4. History of acute kidney injury in the 12 months prior to screening, including specific kidney diseases (e.g., acute interstitial nephritis, acute glomerular and vasculitic renal diseases); non-specific conditions (e.g., ischemia, toxic injury); as well as extrarenal pathology (e.g., prerenal azotemia and acute post renal obstructive nephropathy)~5. Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy initiated or dose changed in the 4 weeks prior to screening~6. Urine protein to creatinine ratio (UPCR) at screening \> 0.5 g/g or mg/mg or 500 mg/g and not treated with an ACE inhibitor or ARB~7. Females who are pregnant, planning to become pregnant during the study, or are breast feeding~8. Cardiovascular event (myocardial infarction, unstable angina) in the 6-month period before screening~9. Cerebrovascular event (stroke, transient ischemic attack) in the 6-month period before screening~10. Presence of any medical, emotional, behavioral, or psychological condition that, in the judgment of the Investigator and/or Medical Director, would interfere with the patient's compliance with the requirements of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Pegunigalsidase alfa (Type: EXPERIMENTAL): Pegunigalsidase alfa 2 mg/kg intravenous infusion every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).